Skip to main content

Table 1 Comparison of tumor characteristics between TNBC and non-TNBC patients

From: The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

  TNBC (n = 43)
N (%)
Non-TNBC (n = 53)
N (%)
χ2 P-value Total
Menopausal status Pre 19 (44%) 25 (47%) 0.0851 p = 0.770 44
Post 24 (56%) 28 (53%) 52
Total   43 53    96
Tumor size ≤5 cm 23 (53%) 41(77%) 6.0869 p = 0.013 64
>5 cm 20 (47%) 12 (23%) 32
Total   43 53    96
Grade 1 + 2 33 (77%) 47 (89%) 1.8674 p = 0.171 80
3 8 (19%) 5 (9%) 13
Total   41 52    93
Stage II 10 (23%) 29 (55%) 6.1913 p = 0.012 39
III + IV 24 (56%) 22 (42%) 46
Total   34 51    85
Lymph-node Present 33 (77%) 30 (57%) 4.2687 p = 0.038 63
Absent 10 (23%) 23 (43%) 33
Total   43 53    96
Clinical response CR 10 (23%) 41 (77%) 30.4317 p < 0.00001 51
SD 2 (5%) 3 (7%) 5
PD 31 (72%) 9 (17%) 40
Total   43 53    96
Relapse Yes 27 (53%) 9 (23%) 25.8285 p < 0.000001 36
No 10 (23%) 40%77%) 50
Total   37 49    86
  1. Abbreviations: TNBC triple negative breast cancer, CR complete response, SD stable disease, PD progressive disease